Key Highlights
Oxford Biomedica PLC (LSE:OXB) shares gained 2.28% on 27 July 2026, putting the cell and gene therapy specialist among today's stronger UK-listed performers.
The company enters the second half of 2026 with considerable operating momentum. FY2025 constant-currency revenue increased 33% to £170.9 million, while Operating EBITDA turned positive at £8.1 million compared with a £15.3 million loss in FY2024.
More importantly, OXB expects FY2026 revenue of £220–240 million and an Operating EBITDA margin of around 10%, while targeting 25–30% annual revenue growth in both 2027 and 2028.
No fresh negative development was identified on 27 July that would contradict this growth story. The 2.28% gain therefore appears consistent with investor confidence in OXB's revenue visibility, improving profitability and expanding global manufacturing capabilities.
About Oxford Biomedica PLC
Oxford Biomedica, now branded as OXB, is a global contract development and manufacturing organisation specialising in cell and gene therapies.
Rather than depending primarily on developing its own medicines, OXB provides viral-vector development and manufacturing services to biotechnology and pharmaceutical customers.
Its capabilities cover three important viral-vector technologies: lentiviral vectors, adeno-associated viral vectors (AAV) and adenoviral vectors.
This gives the company exposure to the broader growth of cell and gene therapy while spreading risk across multiple customer programmes.
OXB operates an increasingly international manufacturing network spanning the UK, US and France.
Why Did Oxford Biomedica Shares Rise 2.28% on 27 July 2026?
Oxford Biomedica PLC (LSE:OXB) shares rose 2.28% on 27 July 2026, according to the market movement provided.
No single fresh company announcement was identified as clearly explaining the entire daily move. Instead, several existing fundamental factors provide a supportive backdrop.
First, OXB has returned to positive Operating EBITDA after several years of investment.
Second, its contracted order book provides substantial future revenue visibility.
Third, the company has expanded its US manufacturing capabilities, positioning the business closer to one of the world's largest biotechnology markets.
Finally, management continues to forecast significant revenue and margin growth through 2027 and 2028.
These factors can support sentiment toward LSE:OXB, particularly as investors increasingly focus on the transition from rapid revenue expansion toward stronger profitability.
Strong FY2025 Financial Performance
OXB's 2025 results represented an important step in its turnaround.
Revenue increased 33% on a constant-currency basis to £170.9 million, compared with £128.8 million in FY2024.
Operating EBITDA improved dramatically from a £15.3 million loss to an £8.1 million profit. Underlying Operating EBITDA, excluding the Durham acquisition-related effects, was £3.3 million.
The improvement demonstrates that increasing revenue and cost discipline are beginning to produce operating leverage.
For investors, the next question is whether OXB can sustain that trajectory as its expanded manufacturing network becomes more heavily utilised.
£204 Million Revenue Backlog
One of the strongest elements of OXB's investment case is its contracted revenue visibility.
At FY2025 year-end, the company's revenue backlog had increased approximately 36% to around £204 million, while the contracted value of orders rose approximately 20% to £224 million.
This backlog represents contracted work that can potentially convert into revenue as customer programmes progress.
A growing order book is particularly important for a CDMO because manufacturing projects can extend across multiple stages, from early development through clinical trials and eventually commercial production.
Progressing customers into later-stage and commercial manufacturing can also increase the value and duration of individual relationships.
US Expansion Could Be a Major Catalyst
The United States represents an important strategic growth market for OXB.
During 2025, the company acquired an FDA-approved commercial-scale viral-vector manufacturing facility in Durham, North Carolina.
The facility expands OXB's commercial manufacturing capacity and positions the company closer to major US biotechnology customers.
Management expects FY2026 performance to be second-half weighted partly because of the ramp-up of Durham revenues and technology transfers in France.
Successful utilisation of this additional capacity could therefore become one of the most important drivers of revenue and margin expansion.
Bristol Myers Squibb Agreement
Another significant commercial development is OXB's multi-year commercial supply agreement with Bristol Myers Squibb.
The agreement covers manufacturing and supply of lentiviral vectors for BMS CAR-T programmes and provides further evidence of OXB's ability to attract major pharmaceutical customers.
Commercial-stage agreements are particularly valuable because they can potentially generate larger and more durable manufacturing volumes than early-stage development contracts.
Further progression of customers from clinical development toward commercial manufacturing could therefore materially improve OXB's revenue mix.
FY2026 Growth Outlook
Management's financial targets remain ambitious.
For FY2026, OXB expects:
- Revenue of £220–240 million
- Operating EBITDA margin of approximately 10%
- Continued strong commercial momentum
- Increasing utilisation of expanded global manufacturing capacity
For 2027 and 2028, management expects 25–30% year-on-year revenue growth, with Operating EBITDA margin targeted at at least 20% in 2027.
Longer term, OXB believes Operating EBITDA margins could approach approximately 30% as manufacturing capacity becomes more fully utilised.
If achieved, this would represent a substantial transformation in the company's earnings profile.
Key Growth Catalysts
Several factors could drive further growth for LSE:OXB.
The most important include converting the £204 million revenue backlog, signing additional pharmaceutical customers, ramping up Durham production and increasing utilisation across the global manufacturing network.
Later-stage customer programmes represent another important opportunity because commercial manufacturing contracts can potentially be substantially larger and longer lasting.
OXB has also launched a fast-track offering for its AAV and lentiviral vector platforms designed to accelerate the pathway to GMP manufacturing by up to nine months, responding to demand from biotechnology customers seeking shorter development timelines.
Valuation Discussion
Traditional P/E valuation remains less useful for LSE:OXB while the company is transitioning from losses toward sustainable profitability.
Investors may instead consider:
- Enterprise value-to-revenue
- EV/EBITDA
- Revenue growth
- Revenue backlog
- Contracted orders
- Operating EBITDA margins
- Cash generation
The key valuation question is whether OXB can successfully convert rapid revenue growth into durable margins.
A company generating £220–240 million of revenue at approximately 10% EBITDA margins has very different economics from the same business operating at the company's longer-term target approaching 30%.
Margin progression therefore deserves as much attention as headline revenue growth.
Key Risks
Execution represents one of OXB's biggest risks.
The company has expanded manufacturing capacity significantly, meaning utilisation needs to increase sufficiently to generate attractive returns on that investment.
Customer-programme risk is also important. Biotechnology programmes can experience clinical setbacks, regulatory delays or funding problems, potentially affecting manufacturing demand.
OXB also expects approximately £60 million of aggregate capital expenditure across 2026 and 2027, reflecting continued investment in growth capacity.
Other risks include customer concentration, biotechnology funding conditions, regulatory requirements, foreign exchange movements and delays in converting contracted orders into recognised revenue.
Conclusion
Oxford Biomedica PLC (LSE:OXB) shares gained 2.28% on 27 July 2026, with the advance occurring against a strong fundamental growth backdrop rather than an obvious single-day corporate catalyst.
OXB delivered 33% constant-currency revenue growth to £170.9 million in FY2025, returned to positive Operating EBITDA and finished the year with approximately £204 million of revenue backlog.
Management now expects FY2026 revenue of £220–240 million and an Operating EBITDA margin around 10%, followed by 25–30% annual revenue growth in 2027 and 2028.
Future performance for LSE:OXB will likely depend on backlog conversion, Durham capacity utilisation, new pharmaceutical contracts, progression of customers toward commercial manufacturing and successful delivery of the company's ambitious margin targets.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...